World Artificial Organs Market

World Artificial Organs Market

This report analyzes the worldwide markets for Artificial Organs in US$ Million. The major product segments analyzed are Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. Annual forecasts are provided for the period of 2003 through 2015. The report profiles 55 companies including many key and niche players worldwide such as Abbott Laboratories, Abiomed Inc., Arbios Systems, Inc., Asahi Kasei Kuraray Medical Co., Ltd., Baxter International, Inc., F. Hoffmann-La Roche Ltd.., Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care North America, Inc., Fresenius Kawasumi, Gambro AB, HepaLife Technologies, Inc., Jarvik Heart, Inc., MC3, Inc., Medtronic, Inc., MicroMed Cardiovascular, Inc., Nikkiso Co., Ltd., Nipro Corporation, SynCardia Systems, Inc., Terumo Corporation, Thoratec Corporation, Toray Medical Co., Ltd., Ventracor Limited, Vital Therapies, Inc., WorldHeart Corporation, and Xenogenics Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ARTIFICIAL ORGANS MCP-1126
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Artificial Organs I-3
Artificial Heart I-3
Artificial Kidneys I-4
Artificial Liver I-4
Artificial Pancreas I-4
Artificial Lungs I-4


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Artificial Organs Revolutionize Medical Technology Industry II-1
Current and Future Analysis II-1
Market Outlook II-2
Opportunities Abound for Bioartificial Organs II-2
Bionics to Play Crucial Role II-3
Economic Situation Plays a Pivotal Role in ESRD Treatment
Accessibility II-3
Table 1: Number of Dialysis Patients by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific, Latin America and
Rest of World for the Year 2006 (includes corresponding
Graph/Chart) II-4
Growth Drivers II-4
Growth Inhibitors II-5

2. Market Trends and Issues II-6
Higher Development Costs and Lengthy Regulatory Process -
Stumbling Blocks for Product Commercialization II-6
Lack of Requisite Expertise - Hindering Implantation Process II-6
Alliances to Play a Key Role II-6
Aging Population - A Boosting Factor II-6
Anemia - A Growing Concern among Renal Failure Patients II-6
Swelling ESRD Patient Population Spurs Dialyzers Growth II-7
Growing Need for Efficient Control and Easy Usage II-7
Expiry of Warranty Provides New Opportunities II-7
Xenotransplantation - Other Alternative to Donor Organ Shortage II-7
Artificial Organs from Cloned Animal Cells - A Promising Trend II-7
Immunosuppressants Hold Promise in Artificial Organs Market II-8
Move Towards Smaller Implantable Devices II-8
Barriers to Entry Significantly High in Dialyzers Market II-8
Reuse of Dialyzers - A Major Issue in Dialysis Industry II-8
Poor Reimbursement Environment Stymies Innovation II-8
Pricing Trends in Artificial Organs II-9

3. Competitive Scenario II-10
Competition Heating Up in Artificial Pancreas Domain II-10
Fresenius Medical Care - Leads the Worldwide Dialysis
Equipment and Supplies Market II-10
Table 2: Leading Players in the Worldwide Dialysis Equipment
and Supplies Market (2006) - Percentage Breakdown of Sales
for Fresenius Medical Care ,Baxter, Gambro and Others
(includes corresponding Graph/Chart) II-11

Table 3: Leading Players in the Worldwide Hemodialysis
Equipment and Supplies Market (2006) - Percentage Breakdown
of Sales for Fresenius Medical Care, Gambro, Baxter and
Others (includes corresponding Graph/Chart) II-11

Table 4: Leading Players in the Worldwide Peritoneal Dialysis
Equipment and Supplies Market (2006) - Percentage Breakdown
of Sales for Baxter, Fresenius Medical Care, Sonstige and
Gambro (includes corresponding Graph/Chart) II-11
Competitive Landscape of Artificial Kidney or Dialyzers Market II-11
Table 5: Leading Players in the Worldwide Dialyzers Market
(2007): Percentage Breakdown of Unit Output for Fresenius
Medical Care, Gambro and Others (includes corresponding
Graph/Chart) II-12
Synthetic Dialyzers to Attain Mainstay II-13
Asahi Kasei Medical Dominates Japanese Dialyzers Market II-13
Table 6: Leading Players in the Japanese Kidney Dialyzers
Market (2005 & 2006) - Percentage Breakdown of Sales for
Asahi Kasei, Nipro, Kawasumi, Toray and Others (includes
corresponding Graph/Chart) II-13
Competitive Landscape of Ventricular Assist Devices II-13
Various Ventricle Assist Devices II-14
Thoratec - Leads the VADs Market II-14
Table 7: Leading Players in the Worldwide VADs Market (2005
& 2006) - Percentage Breakdown of Sales for Thoratec,
Abiomed, WorldHeart and Others (includes corresponding
Graph/Chart) II-15
Liver Assist Devices Competitive Landscape II-15
Various Liver Assist Devices II-16
Core Competitive Factors II-16

4. Product Overview II-17
Artificial Organs II-17
Categorization of Artificial Organs II-17
External Artificial Organs II-17
Internal or Implantable Artificial Devices II-17
Artificial Heart II-17
Total Artificial Heart (TAH) II-18
Ventricle Assist Device (VAD) II-18
Table 8: Distribution of Various Uses of VADs (includes
corresponding Graph/Chart) II-18
Right Ventricular Assist Systems (RVAS) II-18
Left Ventricular Assist Systems (LVAS) II-18
Categorization of LVAS II-18
First Generation LVAS II-18
Second Generation LVAS II-19
Third Generation LVAS II-19
Benefits of LVAS II-20
Major Limitations and Complications of VADs II-20
Infection II-21
Internal Bleeding II-21
Thrombus II-21
Dependability II-21
Cost II-21
Table 9: Average Selling Price per Unit (includes
corresponding Graph/Chart) II-22
Table 10: Distribution of Direct Costs for Heart Failure
in the US (2004) (includes corresponding Graph/Chart) II-22
Natural Human Heart II-22
Heart Diseases II-23
Congenital Heart Disease II-23
Congestive Heart Failure II-23
Types of Heart Failure II-23
Diastolic Heart Failure II-23
Systolic Heart Failure II-23
Artificial Heart - A Historical Perspective II-23
Major Milestones in Artificial Heart Development II-24
Jarvik-7 II-24
AbioCor Total Artificial Heart II-25
Major Advancements in AbioCor Over Jarvik-7 II-25
CardioWest Temporary Total Artificial Heart II-26
DuraHeart LVAS II-26
HeartSaverVAD II-27
VentrAssist Left Ventricular Assist Device II-27
Artificial Kidney (Dialyzer) II-27
Limitations of Artificial Kidney II-28
Types of Dialysis II-28
Hemodialysis II-28
Peritoneal Dialysis II-29
Advances in Artificial Kidney Technology II-29
Bioartificial Kidneys II-30
Limitations of Bioartificial Kidneys II-30
Hindrances to Develop Implantable Artificial Kidney II-31
Artificial Kidneys - A Historical Perspective II-31
Artificial Liver II-31
Overdose of Drugs - A Leading Cause for Liver Damage II-32
Categorization of Liver Devices II-32
Mechanical Systems II-33
Liver Dialysis Unit™ II-33
Molecular Adsorbents Recirculating System II-33
SEPET II-33
Bio-Artificial Systems II-34
Capillary Hollow Fiber Systems II-35
Direct Perfusion Systems II-35
Entrapment Based Systems II-35
Major BAL Devices II-36
Extracorporeal Liver Assist Device (ELAD) II-36
Cellular Components II-36
Types of Bioreactor II-36
HepatAssist-2™ Bioartificial Liver System II-36
Hybrid Artificial Liver Support System II-37
History of Artificial Liver II-37
Liver Assist Devices - Major Milestones II-38
Nonbiological Method Introduction Time Line II-38
Biological Method Introduction Time Line II-38
Artificial Pancreas II-38
Insulin Pumps - Historical Perspective II-39
Bioartificial Pancreas II-40
Nanotechnology in Artificial Pancreas II-40
Medtronic Minimed, Inc Products II-41
External Artificial Pancreas II-41
Implantable Artificial Pancreas II-41
MiniMed Paradigm® REAL-Time Insulin Pump and CGM System II-41
Guardian® RT CGM System II-41
Abbott Products II-41
FreeStyle Navigator CGM System II-41
CozMore Insulin Technology System II-42
Artificial Lungs (Oxygenator) II-42
About Human Lungs II-42
Types of Artificial Lung II-42
Intravenous Membrane Oxygenator II-43
Hattler Respiratory Catheter II-43
MC3 Pulmonary Assist Device II-43
In-Series II-43
In-Parallel II-43
BioLung II-43
Heart-Lung Bypass Machine II-44
Role of Artificial Lungs during Surgery II-44
Direct Contact Device II-44
Indirect-Contact Type-Membrane Devices II-44
Biorubber to be used in Artificial Lungs II-45
History of Artificial Lungs II-45
An Overview of Tissue Engineering II-45

5. Introduction to Biomaterials II-47

6. Organ Transplantation II-48
Sources of Donor Organs II-48
Table 11: US Recent Past, Current & Future Analysis for
Kidney Transplant Donations by Donor Type - Cadaveric and
Living in Units for Years 2001 through 2010 (includes
corresponding Graph/Chart) II-48

Table 12: US Historic Review for Kidney Transplant Donations
by Donor Type - Cadaveric and Living in Units for Years 1991
through 2000 (includes corresponding Graph/Chart) II-49

Table 13: US Recent Past, Current & Future Analysis for Liver
Transplant Donations by Donor Type - Cadaveric and Living in
Units for Years 2001 through 2010 (includes corresponding
Graph/Chart) II-49

Table 14: US Historic Review for Liver Transplant Donations
by Donor Type - Cadaveric and Living in Units for Years 1991
through 2000 (includes corresponding Graph/Chart) II-49

Table 15: US Recent Past, Current & Future Analysis for Heart
Transplants -Donations by Cadaveric Donor Type in Units for
Years 2001 through 2010 (includes corresponding Graph/Chart) II-50

Table 16: US Historic Review for Heart Transplant Donations
by Donor Type - Cadaveric and Living in Units for Years 1991
through 2000 (includes corresponding Graph/Chart) II-50

Table 17: US Recent Past, Current & Future Analysis for
Pancreatic Transplant Donations by Donor Type - Cadaveric and
Living in Units for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-50
Major Milestones in Organ Transplantation II-51
US Organ Transplant Facts II-51
Shortage of Donor Organs Restricts Transplantation Procedures II-51
Table 18: Survival Percentage of Transplanted Organs (
includes corresponding Graph/Chart) II-52
Table 19: Waiting List of Patients in the US as of July 2007
(includes corresponding Graph/Chart) II-53

Table 20: Waiting List of Active and Inactive Patients in the
US for Years 2004 & 2005 (includes corresponding Graph/Chart) II-53
Organ Rejection - A Major Barrier to Transplantation II-53
Other Issues for Organ Transplantation II-54
Combined Organ Transplantation - Gaining Attention II-54

7. Regulatory Environment II-55
Regulatory Environment in the US II-55
Regulatory Environment in Europe II-56

8. Product Innovations/Introductions II-57
Gambro Unveils AK 96™ Dialyzer II-57
Nipro Introduces Artificial Kidney Dialyzer in Overseas Markets II-57
University of Michigan Develops Artificial Lungs II-57
USC Researchers Develop Argus II Retinal Prosthesis System for
Retinal Implant II-57
Researchers Develop Cell Manipulation Technique for Organ
Regeneration Process II-58
Terumo to Introduce First CE Mark LVAS in Europe II-58
Advanced Technique for Nerve Re-Growth Developed II-58
JDRF Develops Artificial Pancreas II-58
Direct Attachment of Artificial Limbs Technique Developed II-59
Artificial Pancreas to Generate Hope for Young Diabetics II-59
Artificial Liver Developed Using Stem Cells II-59
Artificial Liver Device from HepaLife II-59
Researchers Develop Human Nephron Filter II-60
Ventracor Completes Pilot Trial of VentrAssist II-60
National Cardiovascular Center Develops Completely Implantable
Wireless Artificial Heart II-60
InnovaMedica Reveals Prototype for Economical Artificial Heart II-61
Researchers Develop Membrane-Based Microscopic Device II-61

9. Recent Industry Activity II-62
Thoratec Receives FDA Approval for HeartMate II® II-62
Asahi Kasei Institutes a Sales Subsidiary in Taiwan II-62
Arbios Seeks CE Marking for SEPET™ II-62
Gambro Teams up with Debiotech for Developing Peritoneal
Dialysis Cycler II-62
Arbios Obtains US FDA Approval for Initiating Clinical Trial
for SEPET™ II-63
Abiomed Obtains HDE Supplement Approval from FDA for AbioCor®
Implantable Artificial Heart II-63
Ventracor Obtains CE Marking for VentrAssist™ LVAD II-63
Fresenius Medical Care Takes Over Renal Solutions, Inc. II-63
Arbios Inks Exclusive Agreement with NxStage for SEPET™ II-63
WorldHeart Completes First Multi-Day Animal Study of
PediaFlow™ VAD II-64
Xcorporeal, Inc. Completes Merger with CT Holdings II-64
Nikkiso Collaborates with Nipro for Overseas Launch of its
Dialysis Systems II-64
Ege University to Initiate Artificial Heart Project II-64
Vascutek Buys Kohler Chemie’s Heart Valve Business II-64
NovaThera Partners with NovaLung to Develop Advanced
Artificial Lung II-64
Aksys Quits Kidney Dialysis Machines Business II-65
Twardowski Terminates License Agreement with Aksys II-65
Asahi Kasei Medical Fortifies Competence in Artificial Kidney
Production II-65
Fresenius Medical Care Enhances Dialyzer Output II-65
HepaLife Appoints Stem Cell Systems for Bioreactor Development II-65
Hanger Orthopedic Acquires Regional Artificial Limb & Brace II-65
Gambro Acquires Hemapure II-66
Fresenius Medical Care Snaps Up Renal Care Group II-66
CLSI Teams Up with DTS II-66
Abiomed to Foray into the Indian Market II-66
Asahi Kasei Medical to Double Artificial Kidney Production in
China II-66
Thoratec Bags FDA Approval for IDE Supplement for HeartMate II
Phase II Trial under CAP II-66
SynCardia Systems Obtains CE Mark to Sell EXCOR® TAH-t Mobile
Driver with CardioWest™ TAH-t in Europe II-67
FDA Grants Approval for Medtronic’s Guardian® Real- Time CGM
System II-67
DexCom Bags FDA Approval for STS Continuous Glucose Monitoring
System II-67
Vital Therapies Obtains FDA Guidance to Ship ELAD to China II-67
MC3 Secures Phase I STTR Grant from NHLBI to Develop Pump-
Oxygenator II-68
Pauley Heart Center Implants First CardioWest TAH-t on East Coast II-68
LDS Hospital Team Implants WorldHeart’s New Artificial Heart
Device in Greece II-68
Novacor LVAS Support Recipient Completes Five Years II-68
SynCardia Systems to Increase CardioWest TAH-t Transplant
Hospitals II-69
National Quality Care Divests Dialysis Unit to Kidney Dialysis
Center II-69
Medtronic Gains FDA Approval for Mini Med Paradigm® REAL-Time
System II-70
MicroMed Receives CE Mark Extension for DeBakey VAD® System II-70
Thoratec Files Data On HeartMate II LVAS for Pre-Market Approval II-70
Arbios Systems Receives FDA Allowance to Expand Eligibility
Criteria for SEPET™ Liver Assist Device II-70
Abiomed’s AbioCor® Artificial Heart Receives FDA Approval II-71
Abiomed’s IMPELLA 5.0 Receives Conditional IDE Approval II-71
WorldHeart Makes Synergistic Purchase of MedQuest II-72
Nipro Takes Over Artificial Lung Business from Dainippon Ink
and Chemicals II-72
Baxter Inks Pact with Gambro Renal Products II-72
Xenogenics Bags Patent for Synthetic Bio-Liver Device II-72
Gambro Bags FDA Approval for MARS for Drug Overdose and Poisoning II-73
Einstein Medical Center Participates in Artificial Liver
Support Device’s Clinical Trail II-73
SynCardia Announces First CardioWest TAH-t Implantation at The
Cleveland Clinic II-73
SynCardia Announces Implantation of CardioWest™ TAH-t for
Destination Therapy in Germany II-73
Australian Patients Receive Jarvik 2000 II-73
WorldHeart Bags Three Patents for Ventricular Assist Pumps II-74
Asahi Kasei Medical’s First APS™ Dialyzers Assembly Line
Commences Operations II-74
Arrow International Halts LionHeart LVAS II-74
Arbios Systems Takes Over Circe Biomedical’s Bioartificial
Liver Assets II-74
Roche Makes a Synergetic Purchase of Disetronic II-74
MultiCell Technologies Merges with Exten Industries II-75
HepaLife Technologies Expands Cooperative Research Agreement
Scope II-75
MedQuest Wins Contract from NIH to Develop LVAD for Infants II-75
Jarvik Heart Receives Contract from NIH to Develop VADs for
Children II-75
SynCardia Receives FDA Approval for CardioWest™ Temporary
Total Artificial Heart II-75
FDA Grants Approval for SynCardia Systems’ Partial Artificial
Heart II-76
Thoratec Obtains FDA approval for Implantable Ventricular
Assist Device II-76
FDA Grants Approval to World Heart’s Novacor® LVAS for
Destination Therapy II-76
MicroMed Technology Receives Approval for DeBakey VAD Child
Heart Pump II-77
FDA Awards Orphan Drug Designation for Core Component of Vital
Therapies’ ELAD II-77
SynCardia Systems Licenses Technology from MEDOS II-77
MicroMed Technology Announces Implantation of First DeBakey
VAD for Destination Therapy II-77
Vital Therapies Takes Over VitaGen Assets II-77
Advanced Biotherapy Inks Agreement with Russian Federation
Ministry of Health/State Institute of Transplantation and
Artificial Organs II-78
Novalung Signs Agreements with MC3 II-78

10. Focus on Select Global Players II-79
Abbott Laboratories (USA) II-79
Abiomed Inc (USA) II-79
Arbios Systems, Inc. (USA) II-79
Asahi Kasei Kuraray Medical Co., Ltd (Japan) II-80
Baxter International, Inc. (USA) II-80
F. Hoffmann-La Roche Ltd. (Switzerland) II-80
Fresenius Medical Care AG & Co. KGaA (Germany) II-81
Fresenius Medical Care North America, Inc. II-81
Fresenius Kawasumi (Japan) II-82
Gambro AB (Sweden) II-82
HepaLife Technologies, Inc. (USA) II-82
Jarvik Heart, Inc. (USA) II-83
MC3, Inc. (USA) II-83
Medtronic, Inc. (USA) II-83
MicroMed Cardiovascular, Inc. (USA) II-84
Nikkiso Co., Ltd. (Japan) II-84
Nipro Corporation (Japan) II-84
SynCardia Systems, Inc. (USA) II-85
Terumo Corporation (Japan) II-85
Thoratec Corporation (USA) II-85
Toray Medical Co., Ltd. (Japan) II-86
Ventracor Limited (Australia) II-86
Vital Therapies, Inc. (USA) II-86
WorldHeart Corporation (USA) II-87
Xenogenics Corporation (USA) II-87

11. Global Market Perspective II-88
Table 21: World Recent Past, Current & Future Analysis for
Artificial Organs by Product Segment -Artificial Heart,
Artificial Kidneys, Artificial Liver, Artificial Pancreas and
Artificial Lungs Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2010
(includes corresponding Graph/Chart) II-88

Table 22: World Long-term Projections for Artificial Organs by
Product Segment -Artificial Heart, Artificial Kidneys,
Artificiasl Liver, Artificial Pancreas and Artificial Lungs
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-89

Table 23: World 8-Year Perspective for Artificial Organs by
Product Segment - Percentage Breakdown of Dollar Sales for
Artificial Heart, Artificial Kidneys, Artificial Liver,
Artificial Pancreas and Artificial Lungs Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-90

Table 24: World Recent Past, Current & Future Analysis for
Artificial Kidneys/Dialyzers by Geographic Region - USA,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
East and Latin American Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2010 (includes corresponding Graph/Chart) II-91

Table 25: World Long-term Projections for Artificial
Kidneys/Dialyzers by Geographic Region - USA, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
American Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-92

Table 26: World 8-Year Perspective for Artificial
Kidneys/Dialyzers by Geographic Region- Percentage Breakdown
of Dollar Sales for USA, Canada, Japan,Europe, Asia-Pacific
(excluding Japan), Middle East,and Latin American Markets for
Years 2003,2008 & 2012 (includes corresponding Graph/Chart) II-93

Table 27: World Recent Past, Current & Future Analysis for
Insulin Pumps (External) by Geographic Region - USA,Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart) II-94

Table 28: World Long-term Projections for Insulin Pumps
(External) by Geographic Region - USA, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-94

Table 29: World 8-Year Perspective for Insulin Pumps External)
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Europe and Rest of World Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-95


III. COMPETITIVE LANDSCAPE